INmune Bio rises as UK backs plan for testing rare skin disease therapy in children

Inmune Bio

25/06/2026 12:17

** Shares of biotech firm INmune Bio INMB.O rise 13% to $1.51 premarket
** Co says UK regulator approved pediatric plan for Ebstrocel, a cell therapy for recessive dystrophic epidermolysis bullosa, a rare genetic disease that causes very fragile skin and chronic wounds
** Says decision clears key step toward filing to sell the drug in Britain later this year
** Says review took under three months versus typical ~10 months after it sought accelerated review due to urgent need
** Says feedback already built into upcoming trial, keeping 2026 UK, EU filings and early 2027 U.S. submission on track
** Says approval could enable conditional access while further trials continue
** As of last close, stock down 13% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))